Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on opening a special settlement account for cash management of raised funds
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Annual Results Pre-loss Announcement
Announcement of Resolutions of the 9th Meeting of the 2nd Board of Supervisors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the use of some temporarily idle funds raised for cash management
CITIC Securities Co., Ltd. inspection opinions on the use of some temporarily idle funds raised by Jiangsu Yahong Pharmaceutical Technology Co., Ltd. for cash management
Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that the APL-2302 clinical trial application was approved by the State Drug Administration
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that the APL-2302 clinical trial application was approved by the State Drug Administration
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (January 10, 2025)
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the implementation results of share repurchase
Inspection opinions of CITIC Securities Co., Ltd. on the initial public offering of some restricted shares of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement on the initial public offering of some restricted shares of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on shareholders\' voluntary commitment to extend the share lockdown period
Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding transactions
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Table_2024 Third Quarter Results Briefing
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on the release of data related to the APL-1702 international multi-center phase III clinical trial at the 2024 International Papillomavirus Conference
Yahong Pharmaceutical: Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that APL-1706 was approved for marketing by the State Drug Administration
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that APL-1706 was approved for marketing by the State Drug Administration
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Investor Relations Activity Record Form (November 5, 2024)
Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding